Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,862 matching trials from the live ClinicalTrials.gov search.

Filters: Chapel Hill, North Carolina Clear all

Conditions: Degenerative and Traumatic Pathology of the Knee, Degenerative and Traumatic Pathology of the Shoulder and Elbow, Degenerative and Traumatic Pathology of the Foot and Ankle, Degenerative and Traumatic Pathology of the Hand and Wrist, Degenerative and Traumatic Pathology of the Hip
Interventions: Not listed
Lead sponsor: Arthrex, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 12,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 220
States / cities: Birmingham, Alabama • Montgomery, Alabama • Anchorage, Alaska + 171 more

Conditions: Schizophrenia
Interventions: Ziprasidone; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 6 Years to 19 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 4
States / cities: Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more

Conditions: Aortic Arch Dissection, Aortic Arch Aneurysm
Interventions: GORE® TAG® Thoracic Branch Endoprosthesis; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 24
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Metastatic Colorectal Cancer
Interventions: Regorafenib; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 70 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Rochester, Minnesota • Rochester, New York • Chapel Hill, North Carolina + 1 more

Conditions: COPD
Interventions: Home PIFR monitoring with InCheck Dial; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Carfilzomib, Daratumumab, Dexamethasone, Quality-of-Life Assessment, Selinexor; Drug · Biological · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Hackensack, New Jersey • Syracuse, New York • Chapel Hill, North Carolina + 1 more

Conditions: Systemic Lupus Erythematosus
Interventions: belimumab, Placebo; Biological
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Hidradenitis Suppurativa
Interventions: Mediterranean Diet Counseling, Mediterranean Food Support; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: COVID-19
Interventions: Standard implementation webinar and online training, Virtual facilitation; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: No Disease, Mitochondria Health, Longevity, Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult, Healthy Volunteers
Interventions: Kaempferol; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: New York, New York • Chapel Hill, North Carolina • Pittsburgh, Pennsylvania

Conditions: Sarcoma
Interventions: GRID therapy; Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: paclitaxel; Drug
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 44
States / cities: Phoenix, Arizona • Los Gatos, California • Orange, California + 38 more

Conditions: HIV-1 Infection
Interventions: B/F/TAF, NRTIs, Third Agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 82
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost Sodium 314d Modified Release Tablets, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more

Conditions: Preeclampsia
Interventions: Dietary Supplement/Vitamins, Placebo for Vitamin C and Vitamin E; Drug
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: Female only
Enrollment: 10,154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 16
States / cities: Birmingham, Alabama • Chicago, Illinois • Detroit, Michigan + 13 more

Conditions: Anemia, Sickle Cell
Interventions: NP Battery, MRI; Behavioral · Procedure
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 21 Years to 55 Years
Enrollment: 212 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Hollywood, Florida + 8 more

Conditions: Hematologic Disorder, Bleeding Disorder, Connective Tissue Disorder, Hemophilia, Thrombosis, Von Willebrand Diseases, Thrombophilia, Rare Bleeding Disorder, Platelet Disorder, Factor IX Deficiency, Factor VIII Deficiency, Thalassemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: American Thrombosis and Hemostasis Network; Network
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 76
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 60 more

Conditions: Crohn's Disease
Interventions: vedolizumab, Placebo; Drug · Other
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 40
States / cities: Lafayette, Colorado • Hamden, Connecticut • Gainesville, Florida + 36 more

Conditions: X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency, CVID, Common Variable Immunodeficiency, Primary Antibody Deficiencies, Secondary Hypogammaglobulinemia
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 6 Months and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: St. Petersburg, Florida • Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Colorectal Cancer, Colorectal Cancer Stage I
Interventions: E-learning module; Other
Lead sponsor: Althaia Xarxa Assistencial Universitària de Manresa; Other
Eligibility: 28 Years and older
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV-1-infection
Interventions: Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 40
States / cities: Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more

Conditions: Overweight and Obesity, Adiposity, Nutrient; Excess, Physical Activity
Interventions: Nutrition and Physical Activity Intervention, English for Second Language Intervention; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 3 Years to 50 Years
Enrollment: 578 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Developmental Cochlear Nerve Deficiency, Acquired Cochlear Nerve Deficiency, Cochlear Aplasia, Post-meningitis Cochlear Ossification, Cochlear Malformation
Interventions: Auditory Brainstem Implantation in Children; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Months to 17 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tardive Dyskinesia, Antipsychotic Agents
Interventions: Pyridoxine, Placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

Web Based Orthopaedic Sports Medicine Registry

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study

Regorafenib in Metastatic Colorectal Cancer

Peak Inspiratory Flow Rates in Patients With COPD

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

Mediterranean Dietary Intervention for HS

COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists

Kaempferol Absorption and Pharmacokinetics Evaluation

GRID Therapy for Extremity Soft Tissue Sarcoma

Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

Beraprost-314d Added-on to Tyvaso® (BEAT)

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

COVID-19 Vaccine Responses in PIDD Subjects

Web-based Learning Module on Optical Diagnosis of Early Colorectal Cancer

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

Healthy Mothers-Healthy Children Nutrition

Auditory Brainstem Implantation in Young Children

Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia